Source-grounded facts extracted from Quanterix Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Quanterix Corp shareholders rejected Approve an amendment and restatement of the Company's 2017 Employee, Director and Consultant Equity Incentive Plan to implement certain equity compensation best practices and extend the term of the 2017 Plan through June 9, 2031 at the 2026-06-09 meeting.
“Proposal 4 — Approval of an Amendment and Restatement of the 2017 Plan: For Against Abstain Broker Non-Votes 9,677,232 24,004,124 15,723 5,180,238”
Quanterix Corp shareholders approved Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
“Proposal 3 — Ratification of KPMG, LLP as the Company’s Independent Registered Public Accounting Firm: For Against Abstain Broker Non-Votes 38,728,204 137,595 11,518 0”
Quanterix Corp shareholders approved Advisory vote to approve the compensation of the Company's named executive officers at the 2026-06-09 meeting.
“Proposal 2 — Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers: For Against Abstain Broker Non-Votes 27,679,636 3,881,516 2,135,927 5,180,238”
Quanterix Corp shareholders approved Election of directors at the 2026-06-09 meeting.
“Proposal 1 — Election of Directors: For Withheld Abstain Broker Non-Votes William P. Donnelly 30,927,792 2,757,653 11,634 5,180,238 Ivana Magovčević-Liebisch, Ph.D., J.D. 30,314,520 3,375,724 6,835 5,180,238”
Jason Faessler was appointed as Chief Financial Officer and Treasurer at Quanterix Corp.
“The Board of Directors of Quanterix Corporation (the "Company") has appointed Jason Faessler as the Chief Financial Officer and Treasurer of the Company.”
Michael Miller changed role as Chief Technology and Products Officer at Quanterix Corp.
“Michael Miller, formerly the Chief Operating Officer of the Company, has transitioned to a new role as the Chief Technology and Products Officer of the Company.”
Anthony Catalano was appointed as Chief Operating Officer at Quanterix Corp.
“On May 14, 2026, Anthony Catalano was appointed as the Chief Operating Officer of Quanterix Corporation (the “Company”).”
Vandana Sriram departed as Chief Financial Officer and Treasurer at Quanterix Corp.
“Vandana Sriram will be leaving Quanterix Corporation (the “Company”) and will no longer serve as the Chief Financial Officer and Treasurer of the Company effective June 15, 2026.”
Quanterix Corp reported the first quarter ended March 31, 2026 results: revenue $36.4 million. Guidance reaffirmed.
“except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Quanterix Releases Financial Results for the First Quarter of 2026 Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness”
Quanterix Corp: Adopted amended and restated bylaws to implement majority voting standard for uncontested director elections, replacing plurality standard (effective 2025-08-05).
“On and effective as of August 5, 2025, the Board of Directors (the “Board”) of Quanterix approved and adopted amended and restated bylaws (the “Restated Bylaws”) to implement a majority voting standard for uncontested director elections (in place of a prior plurality standard).”
Quanterix Corp announced a restructuring with charges of approximately $2.5 million.
“savings relate to headcount reductions, which are expected to be substantially completed in the third quarter of 2025. The Company expects to incur expenses of approximately $2.5 million, substantially all of which will be cash expenditures incurred in 2025 for severance. The Company’s estimates are based on a number of assumptions. Actual results may differ”
Quanterix Corp announced a restructuring with charges of approximately $3.3 million affecting Akoya Biosciences, Inc. (newly acquired subsidiary) (certain executives of the Company's newly acquired subsidiary, Akoya Biosciences, Inc.).
“costs and streamlined operations and are expected to result in annualized cash savings of approximately $2.8 million. The Company expects to incur expenses of approximately $3.3 million, substantially all of which will be cash expenditures incurred in 2025 for severance required under Akoya’s Executive Severance Plan. The Company’s estimates are based on a”
Quanterix Corp completed an acquisition involving Akoya Biosciences, Inc. for approximately 7.8 million shares of its common stock and paid approximately $20 million in cash (closed 2025-07-08).
“Effective Time and (ii) the aggregate Per Share Cash Consideration paid by the Company in connection with the transactions contemplated in the Merger Agreement does not exceed $20,000,000. The foregoing summary of the Merger Agreement and the Merger is not complete and is qualified in its entirety by reference to the complete text of the Merger Agreement, which is”
Quanterix Corp engaged KPMG LLP as its auditor.
“On May 9, 2025, the Audit Committee approved the appointment of KPMG LLP (“KPMG”) as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Quanterix Corp dismissed Ernst and Young LLP as its auditor.
“On May 9, 2025, Quanterix Corporation (the “Company”) dismissed Ernst and Young LLP (“EY”) as its independent registered public accounting firm, to be effective following the filing of the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2025.”
Quanterix Corp announced a restructuring with charges of approximately $1.5 million.
“The Company expects to incur expenses of approximately $1.5 million related to the reduction in force, substantially all of which will be cash expenditures incurred in 2025 for severance.”
Martin D. Madaus resigned as Director at Quanterix Corp.
“On March 27, 2025, Dr. Madaus notified the Board of his intention to resign from the Board and each committee of the Board on which he serves no later than the date of the Company's 2025 annual meeting of stockholders”
William P. Donnelly was appointed as Chairman at Quanterix Corp.
“On March 24, 2025, the board of directors (the "Board") of Quanterix Corporation (the "Company") appointed William P. Donnelly to serve as Chairman of the Board, effective immediately.”
Quanterix Corp completed an acquisition involving Emission Inc. for $10 million, with an additional $10 million payable upon completion of certain technical milestones (closed 2025-01-08).
“the terms of the Purchase Agreement, the Company purchased from the Shareholders all of the issued and outstanding shares of capital stock of Emission for an upfront payment of $10 million, with an additional $10 million payable upon completion of certain technical milestones. Additionally, the Shareholders may receive up to an additional $50 million in earnout”
Quanterix Corp reported that prior financial statements should not be relied upon.
“the need to restate certain previously issued financial statements as further described in Item 4.02 below”
Ivana Magovčević-Liebisch was appointed as Director at Quanterix Corp.
“appointed Ivana Magovčević-Liebisch, Ph.D., J.D. to serve on the Board effective immediately.”
Jeffrey T. Elliott was appointed as Director at Quanterix Corp.
“On August 19, 2024, the board of directors (the “Board”) of Quanterix Corporation (the “Company”) appointed Jeffrey T. Elliott to serve on the Board effective immediately.”
Daniel Pikora resigned as Chief Operating Officer at Quanterix Corp.
“Daniel Pikora, former Chief Operating Officer, who resigned from the role on May 21, 2024 and will pursue opportunities outside the Company.”
Michael Miller was appointed as Chief Operating Officer at Quanterix Corp.
“On May 21, 2024, Michael Miller, age 60, was appointed as Chief Operating Officer of Quanterix Corporation”
Quanterix Corp reported first quarter ended March 31, 2024 results: revenue $32.1 million. Guidance reaffirmed.
“to study and enable the early detection of neuro-pathologies such as Multiple Sclerosis, Parkinson’s, and Alzheimer’s disease.” First Quarter Financial Highlights ● Revenue of $32.1 million, an increase of 12.7% compared to $28.5 million in the prior year period. ● GAAP gross margin of 61.2%, an increase of approximately 170 basis points compared to the prior year”
Brian J. Blaser resigned as Director at Quanterix Corp.
“On May 2, 2024, Brian J. Blaser notified Quanterix of his resignation from its Board of Directors, effective as of May 3, 2024.”
Laurie Olson departed as Director at Quanterix Corp.
“received notice from director Laurie Olson that she will not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 3, 2024.”
Quanterix Corp reported the fourth quarter and twelve months ended December 31, 2023 results: revenue $31.5 million, net income Net loss was $12.4 million. Guidance initiated.
“biomarker testing to support the rollout of new Alzheimer’s therapies and to aid providers in the diagnosis of the disease.” Fourth Quarter Financial Highlights ● Revenue was $31.5 million, a 22% increase from $25.8 million for the corresponding prior year period. ● GAAP gross margin was 53.2% as compared to 48.8% for the corresponding prior year period. Non-GAAP”
Quanterix Corp updated its the fourth quarter and year ended December 31, 2023 guidance (reaffirmed).
“Quanterix Corporation (the “Company”) issued a press release announcing that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023”
Quanterix Corp updated its the fourth quarter and year ended December 31, 2023 guidance (reaffirmed).
“On January 10, 2024, Masoud Toloue, the President and CEO of Quanterix Corporation (the “Company”), made a presentation at the 42 nd Annual JP Morgan Healthcare Conference. The presentation included slides (the “Slides”) containing preliminary, unaudited estimated financial information for the fourth quarter and year ended December 31, 2023 (the “Preliminary Financial Information”).”
Quanterix Corp reported Full year 2023 results: revenue $118 to $120 million. Guidance raised.
“Management has increased full-year revenue expectations to be in the range of $118 to $120 million versus the prior range of $110 to $116 million.”
Quanterix Corp reported three months ended September 30, 2023 results: net income Net loss was $7.8 million as compared to $35.1 million for the corresponding prior year period..
“Revenue was $31.3 million, an 18% increase from $26.6 million for the corresponding prior year period.”
William P. Donnelly was appointed as Director at Quanterix Corp.
“On August 17, 2023, the board of directors (the “ Board ”) of Quanterix Corporation (the “ Company ”) appointed William P. Donnelly to serve on the Board and the Audit Committee of the Board, in each case effective immediately.”
Vandana Sriram was appointed as Chief Financial Officer at Quanterix Corp.
“On August 9, 2023, the Company issued a press release announcing the appointment of Vandana Sriram as Chief Financial Officer of the Company, effective August 21, 2023.”
Michael Doyle changed role as Chief Financial Officer and Treasurer at Quanterix Corp.
“Effective as of August 21, 2023, Michael Doyle will cease serving as the Chief Financial Officer and Treasurer of Quanterix Corporation”
Quanterix Corp reported second quarter ended June 30, 2023 results: revenue $31.0 million. Guidance raised.
“today announced financial results for the three months ended June 30, 2023. Second Quarter Financial Highlights ● Total revenue was $31.0 million versus prior year second quarter total revenue of $23.5 million, an increase of 32%. Second quarter revenue also increased 9% sequentially driven by increased Accelerator Lab and consumables revenue. Second quarter revenue includes a one-time benefit of approximately $1.5 million related to product and license agreements. ● GAAP gross margin was 61.7% compared to prior year second quarter GAAP gross margin of 37.1%. Non-GAAP gross margin was 56.4% compared to prior year second quarter non-GAAP gross margin of 29.1%. ● Net loss was $6.1 million compared to prior year second quarter net loss of $24.9 million.”
Quanterix Corp shareholders approved Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
“Proposal 3 — Ratification of Independent Registered Public Accounting Firm : For Against Abstain 30,669,815 37,672 5,885”
Quanterix Corp shareholders approved Advisory vote to approve the compensation of the Company's named executive officers at the 2023-06-07 meeting.
“Proposal 2 — Advisory Vote to Approve the Compensation of the Company's Named Executive Officers : For Against Abstain Broker Non-Votes 26,690,270 239,915 11,803 3,771,384”
Quanterix Corp shareholders approved Election of Class III Directors at the 2023-06-07 meeting.
“Proposal 1 — Election of Directors : For Withheld Broker Non-Votes Brian J. Blaser 26,710,969 231,019 3,771,384 Paul M. Meister 17,804,718 9,137,270 3,771,384”
Quanterix Corp reported full year 2023 results: revenue $99.5 - $106.5. Guidance raised.
“2023 Guidance We have made a modest positive adjustment to our full year 2023 Revenue and Gross Margin % guidance 1 Gross Margin % Expect FY 2023 GAAP gross margin in the high 40s and non-GAAP gross margin in the mid 40s $4.5 2023 Guidance ~$11.0 2022 Actual Revenue ~$94.5 $99.5 - $106.5 $105.5 $104 - $111 (in millions) Pharma Collaboration(s) Core product and services revenue +9% MP YoY Cash Burn Cash burn guidance remains unchanged. Expect cash burn to improve by approximately 10% in 2023 versus 2022 Cash flow positive at $170-$190M in revenue”
Quanterix Corp reported three months ended March 31, 2023 results: revenue $28.5 million, net income -$6.1 million.
“First Quarter 2023 Financial Highlights ● Q1 total revenue was $28.5 million versus prior year Q1 of $29.6 million, a decrease of 4% driven by a decline in instrument revenue. Q1 total revenue increased 10% from Q4 2022 driven by increased consumable revenue. ● Gross margin, a key success indicator of the strategic realignment, saw strong quarter over quarter improvement. Q1 2023 GAAP gross margin was 59.5% versus Q1 2022 GAAP gross margin of 49.3% and Q4 2022 GAAP gross margin of 48.8%. Q1 2023 non-GAAP gross margin was 53.1% versus Q1 2022 non-GAAP gross margin of 43.2% and Q4 2022 non-GAAP gross margin of 41.3%. ● Q1 net loss was $6.1 million versus prior year Q1 of $18.2 million, a decrease of 66%.”
Keith L. Crandell departed as director at Quanterix Corp.
“On April 10, 2023, Quanterix Corporation (the “Company”) received notice from Keith L. Crandell that he will not stand for re-election at the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”), which is expected to be held on June 7, 2023.”
Quanterix Corp reported financial results for fourth quarter and twelve months ended December 31, 2022.
“On March 6, 2023, Quanterix Corporation (“Quanterix”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022 (the “Earnings Release”).”
Brian J. Blaser was appointed as Director at Quanterix Corp.
“On January 6, 2023, the board of directors (the “Board”) of Quanterix Corporation (the “Company”) appointed Brian J. Blaser to serve on the Board effective immediately.”
Quanterix Corp reported financial results for third quarter ended September 30, 2022.
“Quanterix Corporation (“Quanterix”) issued a press release announcing its financial results for the third quarter ended September 30, 2022 (the “Earnings Release”).”
Daniel Pikora was appointed as Chief Operating Officer at Quanterix Corp.
“On September 6, 2022, the Board of Directors of Quanterix Corporation (the “Company”) appointed Daniel Pikora as the Company’s Chief Operating Officer.”
Martin D. Madaus was elected as Chairman of the Board at Quanterix Corp.
“The Company’s current Lead Independent Director, Martin D. Madaus, Ph.D., has been elected to succeed Mr. Hrusovsky as Chairman of the Board, effective as of August 8, 2022.”
E. Kevin Hrusovsky resigned as Executive Chairman at Quanterix Corp.
“his employment as Executive Chairman of the Company’s Board of Directors (the “Board”) has ended and he has resigned as a Director on the Board, both effective as of August 8, 2022.”
John Fry resigned as General Counsel and Secretary at Quanterix Corp.
“On June 21, 2022, John Fry notified Quanterix Corporation (the “Company”) of his resignation as General Counsel and Secretary, effective August 12, 2022 .”
Karen A. Flynn was appointed as Class I Director at Quanterix Corp.
“On June 3, 2022, the board of directors (the “Board”) of Quanterix Corporation (the “Company”) appointed Karen A. Flynn to serve on the Board, effective as of June 6, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.